Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2052W HIGH $5.14
Volume
404.86 K
Value Traded
661.96 K
Short % Float
6.13%
-10.3%Week
-1.21%1 Month
-6.57%3 Month
-59.01%6 Month
-99.18%5 Year
-99.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.48 M
EPS (TTM)
-1.52
P/E Ratio
-
Ent. Value
-21.25 M
Total Shares
44.38 M
Float Shares
44.19 M
Insiders
0.42%
Institutions
26.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VTGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Vistagen Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vistagen Therapeutics, Inc.
334Total events
6Upcoming
68Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutFasedienolClinical Data
Topline data from PALISADE-4 Phase 3 trial of Fasedienol for acute treatment of SAD
Social Anxiety Disordersource ↗
▲Safety Data UpdateFasedienolClinical Data
Achieved minimum ICH safety exposure recommendations across clinical program
Social Anxiety Disordersource ↗
◆Management ChangeCorporate
Appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer
▲Interim AnalysisFasedienolTrial
Preliminary positive data in ongoing open-label extension portion of PALISADE-3 Phase 3 study
Social Anxiety Disordersource ↗
▲Last Patient Last VisitFasedienolTrial
Last patient visit completed in PALISADE-4 Phase 3 study of Fasedienol for acute treatment of social anxiety disorder
Social Anxiety Disordersource ↗
▲IND ClearancerefisoloneIND
FDA Study May Proceed letter for refisolone IND
Vasomotor Symptoms (Hot Flashes) due to Menopausesource ↗
◆Oral PresentationPresentation
Vistagen to present at 46th Annual TD Cowen Healthcare Conference
◆Quarterly UpdateCorporate
Fiscal Year 2026 Third Quarter Results and Corporate Update Conference Call
▼Primary Endpoint MissedFasedienolClinical Data
PALISADE-3 Phase 3 study of intranasal fasedienol did not demonstrate statistically significant improvement on primary endpoint
social anxiety disordersource ↗
▼Topline ReadoutFasedienolClinical Data
Topline results from randomized portion of PALISADE-3 Phase 3 trial announced
Social Anxiety Disordersource ↗
●Poster PresentationPH80Presentation
Poster presentation at The Menopause Society 2025 Annual Meeting
vasomotor symptoms (hot flashes) due to menopausesource ↗
▲Last Patient Last VisitFasedienolTrial
Last patient completed randomized portion of PALISADE-3 Phase 3 trial
social anxiety disordersource ↗
●Quarterly UpdateCorporate
Fiscal year 2026 second quarter financial results and corporate update
▲Enrollment CompleteFasedienolTrial
Last patient completed randomized portion of PALISADE-3 Phase 3 trial
social anxiety disordersource ↗
◆Topline ReadoutFasedienolClinical Data
Topline results of PALISADE-3 Phase 3 trial of fasedienol for acute treatment of social anxiety disorder
social anxiety disordersource ↗
◆Management ChangeCorporate
Appointment of Elissa Cote as Chief Corporate Development Officer
●Quarterly UpdateCorporate
Fiscal year 2025 financial results and corporate update conference call
●Management ChangeCorporate
Appointment of Elissa Cote as Chief Corporate Development Officer
▲Trial InitiationFasedienolTrial
Initiated fasedienol Phase 2 Repeat Dose Study for SAD
social anxiety disordersource ↗
▲Topline ReadoutPH284Clinical Data
Positive results from exploratory Phase 2A study of PH284 in cancer cachexia
cancer cachexiasource ↗
▲Patent GrantedAV-101IP / Competition
USPTO granted patent for AV-101 to treat neuropathic pain, expiring at least 2034
neuropathic painsource ↗
▲Topline ReadoutPH284Clinical Data
Positive results from exploratory Phase 2A study of PH284 in cancer cachexia
cancer cachexiasource ↗
◆Topline ReadoutFasedienolClinical Data
PALISADE-3 Phase 3 top-line results expected in 2025
social anxiety disordersource ↗
●IND SubmissionPH80IND
Planned U.S. IND submission for PH80
vasomotor symptoms (hot flashes) due to menopausesource ↗
●Trial InitiationitruvoneTrial
Preparations and planning for Phase 2B development of itruvone for MDD
major depressive disordersource ↗
●Quarterly UpdateCorporate
Fiscal Year 2025 First Quarter Financial Results and Corporate Update
◆Trial InitiationFasedienolTrial
Initiation of PALISADE-4 Phase 3 trial
Social Anxiety Disordersource ↗
◆Trial InitiationFasedienolTrial
PALISADE-4 Phase 3 trial initiation anticipated
social anxiety disordersource ↗
▲Topline ReadoutFasedienolClinical Data
Positive top-line results from PALISADE-2 Phase 3 trial
social anxiety disordersource ↗
▲Full ResultsitruvoneClinical Data
Completed U.S. Phase 1 trial with favorable safety and tolerability data
major depressive disordersource ↗
●Preclinical PoCitruvonePreclinical
Preclinical data demonstrating undetectable brain and systemic exposure
major depressive disordersource ↗
▲Full ResultsPH80Clinical Data
Positive exploratory Phase 2A data for hot flashes
vasomotor symptoms due to menopausesource ↗
▲Partnership / LicensePH80Corporate
Exclusive Negotiation Agreement with Fuji Pharma for PH80 in Japan
vasomotor symptoms due to menopausesource ↗
▲Primary Endpoint MetFasedienolClinical Data
Positive results from PALISADE-2 Phase 3 trial
social anxiety disordersource ↗
▲Topline ReadoutFasedienolClinical Data
PALISADE-2 Phase 3 trial met primary efficacy endpoint
Social Anxiety Disordersource ↗
●Timing GuidancePH94BPresentation
Planned NDA submission to FDA in 2023
social anxiety disordersource ↗
◆Topline ReadoutPH94BClinical Data
Topline results from PALISADE-2 anticipated in second half of 2022
social anxiety disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How VTGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | fasedienol | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.3x
rNPV / MCap
Top 80%
Micro Cap(rank 528 of 660)
Percentile Rank
Vistagen Therapeutics, Inc. faces pipeline headwinds (26/100), with $473M risk-adjusted pipeline value, led by AV-101 in Major Depressive Disorder (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AV-101 Small moleculeCompletedNCT03078322 | Major Depressive Disorder | Phase 2 | COMPLETED | 180 | Oct 1, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every VTGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| fasedienol | very severe social anxiety disorder | Phase 3 | 2026-09-24 | statistically significant benefit of fasedienol on average SUDS scores during the public speaking challenge; statistically significant improvement following a single dose of fasedienol on average SUDS scores during the PSC; greater numerical improvement after a second dose of intranasal fasedienol taken 10 minutes after the firstRead More | Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety DisorderRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Adler Reid G.Officer (Chief Legal Officer) | Grant/Award | 36,818 60,868 held | $0.19 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VTGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| COMMODORE CAPITAL LP | 0 % (-100 %) | 630.00 K | 2.79 M | 77.06% ( 1.21 M) |
VTGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VTGN ranks across every disease it competes in
Competitive Position is a premium feature
See how VTGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVTGN News
VTGN▼ -19.9%on this news
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Vistagen presented positive exploratory data on fasedienol at Psych Congress 2026, showing potential efficacy in treating very severe social anxiety disorder. Participants in clinical trials exhibited significant improvements in anxiety symptoms compared to placebo. Despite not meeting the primary endpoint in the total population, the findings suggest promise for fasedienol, particularly with repeat dosing.
Read more →VTGN▲ +7.9%on this news· ran to +58% by day 1shared move
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen announced preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 study, showing that fasedienol nasal spray was well-tolerated and led to significant improvements in social anxiety disorder over four months. The data suggests fasedienol's potential effectiveness in real-life social situations. However, the initial randomized study did not meet its primary endpoint.
Read more →VTGNVistagen to Present at Psych Congress 2026
Vistagen announced it will present data on its Phase 3 product candidate, fasedienol nasal spray, at Psych Congress 2026. The presentation will highlight positive efficacy signals in participants with very severe social anxiety disorder. The event is scheduled for September 17 and 18, 2026, in New Orleans.
Read more →VTGNVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Vistagen reported its fiscal year 2027 first quarter results, highlighting exploratory analyses showing improvement in patients with severe social anxiety disorder. The company plans to engage with the FDA regarding a potential Phase 3 pathway for fasedienol. Recent leadership appointments aim to bolster drug development efforts. Despite a net loss of $13 million, the company is focused on cash preservation and strategic opportunities.
Read more →VTGNVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen announced positive topline results from its Phase 2 repeat dose study of fasedienol for social anxiety disorder. The study showed favorable safety and tolerability, with efficacy signals across various endpoints. Notably, patients with severe social anxiety disorder exhibited statistically significant improvements. These findings will inform discussions with the FDA regarding fasedienol's potential registrational pathway.
Read more →VTGN▲ +22.4%on this news
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
SRX Global Inc. has acquired a stake in Vistagen Therapeutics, a late clinical-stage biopharmaceutical company. SRX views Vistagen's shares as undervalued and plans to engage with its leadership to discuss strategies for enhancing shareholder value. This acquisition aligns with SRX's focus on long-term investments in high-conviction companies.
Read more →VTGNVistagen Appoints Douglas J. Williamson to its Board of Directors
Vistagen has appointed Dr. Douglas J. Williamson to its Board of Directors, enhancing its leadership team. Dr. Williamson brings significant experience in neuroscience drug development, having led various programs from early research to commercialization. His expertise is expected to support Vistagen's mission of advancing innovative treatments for unmet medical needs.
Read more →VTGN▼ -70.3%on this news
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has announced topline and post-hoc data from the PALISADE-4 Phase 3 trial of Fasedienol, targeting the acute treatment of social anxiety disorder. The results are part of their ongoing research into effective therapies for this condition. Further details on the findings and implications were not disclosed in the announcement.
Read more →VTGN▲ +20.4%on this news
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen has reported its financial results for the fiscal year 2026, along with a corporate update. The details of the financial performance and any significant developments were not disclosed in the provided text. Further insights into the company's strategies or future plans were also not included.
Read more →VTGNVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has successfully achieved the minimum ICH safety exposure recommendations for its clinical program involving Fasedienol, aimed at treating acute social anxiety disorder. This milestone indicates the company's commitment to safety standards in its drug development process. The achievement may enhance the drug's prospects in clinical trials.
Read more →VTGNVistagen to Participate in Jefferies 2026 Global Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company, will participate in the Jefferies 2026 Global Healthcare Conference from June 2-4, 2026, in New York City. The company plans to hold one-on-one meetings with institutional investors during the event. Vistagen focuses on developing intranasal product candidates aimed at treating various mental health conditions.
Read more →VTGN▲ +5.8%on this news
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Vistagen has appointed Angel S. Angelov, MD, MBA, as its new Chief Medical Officer. This leadership change is aimed at enhancing the company's strategic direction in drug development. Dr. Angelov brings extensive experience in clinical research and development to the role.
Read more →VTGN▼ -7.7%on this news
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen has announced preliminary positive data from the ongoing open-label extension of the PALISADE-3 Phase 3 study for Fasedienol, aimed at treating social anxiety disorder. The results indicate a favorable response to the treatment, suggesting its potential effectiveness. This development marks a significant step in Vistagen's efforts to address mental health issues.
Read more →VTGNVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen has announced the completion of the last patient visit in the PALISADE-4 Phase 3 study, which evaluates fasedienol for the acute treatment of social anxiety disorder. This milestone is crucial for advancing the development of fasedienol as a potential treatment option. The study's results could significantly impact the management of social anxiety disorder.
Read more →VTGNVistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Vistagen has received a 'Study May Proceed' letter from the FDA for its refisolone nasal spray, which is intended to treat vasomotor symptoms associated with menopause. This approval enables the company to continue its Phase 2 clinical development. Refisolone represents a non-hormonal and non-systemic approach to managing these symptoms.
Read more →VTGNVistagen to Participate in Upcoming Investor Conferences
Vistagen (Nasdaq: VTGN) has announced its participation in two upcoming investor conferences in March 2026. The company will engage in one-on-one meetings at the Leerink Healthcare Conference and host a fireside chat at the Stifel 2026 Virtual CNS Forum. Vistagen focuses on developing intranasal product candidates aimed at treating various mental health conditions.
Read more →VTGNVistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company, will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026. CEO Shawn Singh will provide a corporate overview during the event. The company is developing pherines, a new class of intranasal products aimed at treating various mental health conditions without traditional absorption methods.
Read more →VTGNVistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
Vistagen reported its fiscal Q3 2026 financial results and provided updates on its clinical pipeline. The PALISADE-4 Phase 3 trial for fasedienol, targeting social anxiety disorder, is progressing with topline results expected in early 2026, following improvements based on previous trial data. However, the earlier PALISADE-3 trial did not meet its primary endpoint, although safety data remains favorable. The company continues with cash preservation measures and has seen a rise in both research and administrative expenses, contributing to a net loss.
Read more →VTGNVistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
Vistagen will host a conference call on February 12, 2026, to report its fiscal year 2026 third quarter results and provide a corporate update. The call will be accessible via webcast and dial-in, allowing investors to engage with the company's latest developments. Vistagen specializes in developing intranasal therapies aimed at treating various mental health conditions.
Read more →About Vistagen Therapeutics, Inc.
Headquarters343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next VTGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime